Phase 1 Trial of ABY-029 Fluorescence in Patients With Head and Neck Squamous Cell Carcinoma
Latest Information Update: 16 Dec 2025
At a glance
- Drugs ABY 029 (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Diagnostic use
Most Recent Events
- 16 Dec 2025 New trial record